Compare iShares Core S&P 500 ETF (IVV) vs Johnson & Johnson (JNJ) Price & Performance

iShares Core S&P 500 ETFTrade

Johnson & JohnsonTrade

Price performance (Past 24H)

Key statistics

iShares Core S&P 500 ETF vs Johnson & Johnson — how do they compare? iShares Core S&P 500 ETF trades at $777.7, while Johnson & Johnson trades at $261.34 (market cap $628.65B). The key difference: Johnson & Johnson pays a 2.05% dividend while iShares Core S&P 500 ETF pays none. Which is the better fit depends on your goals.

	IVV	JNJ
Sector	Broad Market / Factor	Health
52-Week High	$776.81	$267.24
52-Week Low	$634.93	$174.16
Market Cap	—	$628.65B
Volume	—	6,156,228
Enterprise Value	—	$656.92B
Dividend Yield	—	2.05%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares Core S&P 500 ETF

IVV, tracking the S&P 500, trades at $776.18, down 0.07% with a bullish technical outlook from moving averages but overbought RSI signals. Recent news highlights record highs and institutional activity, with JPMorgan raising its S&P 500 target to 8,000 amid strong earnings growth. The ETF shows resilience despite valuation concerns.

Outlook remains positive due to AI-driven earnings growth, but risks include high valuations and market volatility. Investors benefit from broad market exposure, yet should monitor inflation reports and geopolitical events that could trigger pullbacks.

Johnson & Johnson

Johnson & Johnson (JNJ) trades at $260.88, down 0.36% today, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a net margin of 21.48% and ROE of 25.74%, though valuations like a P/E of 30.14 appear elevated. Recent earnings beat expectations in Q1 and Q2 2026, and the company maintains a 64-year dividend growth streak, with analyst consensus leaning bullish.

Outlook remains positive with a consensus price target of $284.50, offering potential upside, but risks include legal challenges and high debt-to-asset ratio of 24.06% in 2025. Investors benefit from steady dividends and defensive positioning in healthcare, though valuation multiples may limit near-term gains amid economic uncertainty.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

IVV

S&P 500 ETFs forecast strong dividend growth, with IVV leading in 2026 distributions.Seeking Alpha · 4 hours agoBullish WisdomTree U.S. Total Dividend ETF (DTD) rated 'hold' for balanced factors but overlaps 57% with S&P 500 ETFs.Seeking Alpha · 2 days agoNeutral View details →

JNJ

J&J and AbbVie report strong quarters with contrasting dividend and growth strategies.24/7 Wall Street · 21 hours agoBullish HDV's top dividend payers—Exxon, Chevron, J&J, AbbVie—are mostly safe, supporting steady income.24/7 Wall Street · 23 hours agoBullish Revolution Medicines hits $44B market cap with breakthrough RAS cancer drugs, attracting big pharma interest.24/7 Wall Street · 1 day agoBullish View details →

About iShares Core S&P 500 ETF

IVV tracks the performance of the S&P 500 Index, offering low-cost exposure to 500 of the largest US companies. It is a cornerstone for long-term investors seeking broad growth in the US stock market.

About Johnson & Johnson

Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.